Interestingly, both IL6 and TNFα are among the core cytokines involved in cytokine release syndrome (CRS), and IL6 blockade by Tocilizumab is often employed in an attempt to relieve life-threatening aspects of CRS [21,22]. The gene discussed is TNF; the disease is congenital rubella syndrome.